Adequate pain management is important for animals, for both clinical and ethical reasons. Veterinary clinicians strive to minimize pain and distress in animals. To accomplish this goal, veterinarians should be aware of the available analgesic drugs and the biological effects of such drugs in various species of animals.
In companion animals, NSAIDs are commonly used for the treatment of pain. Nonsteroidal anti-inflammatory drugs have central and peripheral activities, and they effectively reduce signs of pain and inflammation in animals with musculoskeletal disease and after surgery.1,2 Additionally, NSAIDs can be used in conjunction with other analgesic drugs (eg, opioids) for multimodal analgesia.3,4
Meloxicam is a commonly used NSAID for animals of various species. Similar to other NSAIDs, meloxicam reduces the production of prostaglandins via inhibition of the activity of COX.5 Because meloxicam preferentially inhibits COX-2 in animals of most species, it may have fewer gastrointestinal tract adverse effects than other types of NSAIDs.6 However, such adverse effects are dose dependent, and the COX-2 specificity of meloxicam is decreased at high doses.7 Therefore, veterinarians should have knowledge of the pharmacokinetics of this drug before prescribing it for animals.8,9
Pain management is important for the successful treatment of various conditions in rabbits. Rabbits commonly develop adverse effects caused by pain and distress and can develop secondary conditions (eg, ileus) if pain is not controlled.10 During recovery from surgery, the potential for development of ileus in rabbits is high and can be potentiated via treatment with opioids.11 Additionally, rabbits do not always develop obvious signs of pain. Therefore, accurate assessment of discomfort in rabbits can be challenging and it is important to administer effective analgesic drugs to such animals. Although meloxicam is not labeled for use in rabbits by the US FDA, it is commonly used for analgesia in such animals.
Two studies12,13 have been conducted to determine the pharmacokinetics of meloxicam in rabbits. Results of those studies12,13 indicate that rabbits eliminate meloxicam faster than animals of many other species; the authors of those studies suggested that a high dose of meloxicam might be necessary to provide adequate analgesia for rabbits during a 24-hour period. However, results of those studies12,13 were different regarding accumulation of meloxicam after administration of multiple doses, and investigators could not recommend use of a dose exceeding 0.3 mg/kg during a 24-hour period because of the study designs. The objectives of the study reported here were to determine the pharmacokinetics of meloxicam (1 mg/kg) in rabbits after oral administration of a single dose and after administration of multiple doses during a 5-day period and to measure plasma biochemical analysis variables to determine the safety of meloxicam at the evaluated dosages. Our hypotheses were that administration of a high dose of meloxicam would cause high plasma concentrations of the drug and that accumulation of meloxicam in plasma would develop during a 5-day treatment period.
Materials and Methods
Animals—Six clinically normal 8-month-old New Zealand white rabbits (Oryctolagus cuniculus; body weight range, 2.41 to 2.89 kg) were included in this study. The rabbits were obtained from a commercial source and were specific pathogen (Pasteurella sp) free. Rabbits were housed individually in stainless steel cages at the research facilities of the Kansas State University College of Veterinary Medicine at a constant temperature (21.11°C) and humidity (60%). Rabbits were exposed to cycles of 16 h of light and 8 h of dark/d and were fed an alfalfa-based pelleted feeda and timothy hay.b Water was available ad libitum. Rabbits were acclimated to the facility for 5 days after their arrival and were habituated to handling prior to initiation of the study. Immediately prior to the start of the study, each rabbit underwent a physical examination, evaluation of a fecal sample, and collection of a blood sample (0.5 mL) from a lateral saphenous or cephalic vein or an auricular artery for determination of Hct and plasma total protein concentration and biochemical analysis variables. All rabbits were determined to be healthy and behaviorally normal. This study was approved by the Institutional Animal Care and Use Committee of Kansas State University.
Experimental design and sample collection—Immediately prior to meloxicam administration, 0.5 mL of blood was collected from each rabbit for determination of baseline values of plasma biochemical analysis variables. Meloxicamc (1 mg/kg) was orally administered to each rabbit; a 3-mL syringe containing the dose of meloxicam was inserted into the diastema, and the drug was slowly administered so that none of the medication escaped the oral cavity. Blood samples (0.5 mL) were collected from a lateral saphenous or cephalic vein or an auricular artery of each rabbit by use of 25-gauge needles and syringes containing heparin. Blood was collected immediately before (0 hours) and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 36 hours after meloxicam administration. This was followed by a 10-day washout period. After the washout period, each rabbit received meloxicam (1 mg/kg, PO) every 24 hours for 5 days. During this time, blood samples (0.5 mL) were collected from each rabbit immediately before and 4 hours after meloxicam administration on each of the first 4 days. On the fifth day, blood samples were collected immediately before and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 36 hours after meloxicam administration. Meloxicam was administered at 24-hour intervals in the present study on the basis of results of other studies12,13 in which the pharmacokinetics of meloxicam in rabbits was determined. Also, the use of this meloxicam administration interval enabled assessment of meloxicam accumulation in the plasma of rabbits. Therefore, 32 blood samples were collected from each rabbit during the study period for determination of meloxicam concentrations. At the final blood collection time, an additional blood sample (0.5 mL) was collected for performance of plasma biochemical analyses. Within 20 minutes after each collection time, blood samples were centrifuged (10 minutes at approx 2,000 × g) and the plasma supernatant was harvested and stored at −70°C until analysis.
Plasma sample analysis—Plasma concentrations of meloxicam were determined via high-pressure liquid chromatographyd and triple quadrupole mass spectrometry.e Plasma samples or rabbit plasma standards (50 μL) were added to 200 μL of internal standard (piroxicam [0.5 μg/mL] in methanol with 0.1% formic acid) to precipitate proteins, vortexed for 5 seconds, then centrifuged for 10 minutes (10,000 × g). Supernatant (200 μL) was transferred to injection vials (injection volume setting, 10 μL). The high-pressure liquid chromatography mobile phase consisted of acetonitrile and formic acid (0.1%) at a flow rate of 0.4 mL/min (85% formic acid [0.1%] from 0 to 0.5 minutes, then a linear gradient to 50% formic acid [0.1%] at 2.5 minutes that was maintained until 3 minutes, followed by a linear gradient to 85% formic acid [0.1%] at 4 minutes; total mobile phase time, 5 minutes). Separation was achieved by use of a C8 columnf at 40°C. The qualifying and quantifying ions for meloxicam were an m/z of 352.09 and 114.90, respectively. The qualifying and quantifying ions for the internal standard (piroxicam) were m/z 332.12 and 95.10, respectively. The ion source voltage was 5,000 V, and the source temperature was maintained at 400°C. The standard curve was linear from 0.01 to 10 μg/mL and was accepted if the correlation coefficient was > 0.99 and predicted values were within the range of values 15% higher or lower than the actual values. The accuracy of the assay at 0.01, 0.1, 0.5, 1, and 5 μg/mL was 100.7%, 99.6%, 97.5%, 98.0%, and 102.2% of the expected value, respectively. The coefficient of variation at 0.01, 0.1, 0.5, 1, and 5 μg/mL was 2%, 4%, 10%, 14%, and 7%, respectively.
Values of plasma biochemical analysis analytes were determined for baseline (before meloxicam administration) and posttreatment (after administration of the last dose of meloxicam) times. These analytes included plasma glucose, BUN, total protein, albumin, globulin (calculated), total calcium, phosphorus, sodium, potassium, chloride, bicarbonate, and total bilirubin concentrations and creatine kinase alanine aminotransferase and alkaline phosphatase activities.
Pharmacokinetic analysis—Values of pharmacokinetic parameters were determined for each rabbit by use of noncompartmental analysis performed with commercially available software.14,15,g The following parameters were determined: AUCinf, AUC area under the first moment curve extrapolated to infinity, λz, terminal half-life, Cmax, mean residence time extrapolated to infinity, and Tmax (a parameter derived from precisely timed blood sampling related to the time the peak plasma concentration occurred). The percentage AUC extrapolated to infinity was also determined by dividing the AUC including all time points > 0.01 μg/mL by AUCinf. The AUCinf was determined by adding the AUC including all time points > 0.01 μg/mL and the last measured plasma concentration/λz. The ratio of the AUC (for the last dose of the multiple meloxicam dose experiment) to the AUCinf (for the single meloxicam dose experiment) was determined to assess plasma accumulation of meloxicam; for this evaluation, it was assumed that steady-state meloxicam concentrations in rabbits were achieved by the time the last dose of meloxicam was administered during the multiple-dose experiment.
Statistical analysis—Values of plasma biochemical analysis variables for baseline and posttreatment blood samples were compared with a paired t test. Values of P < 0.05 were considered significant.
Results
Meloxicam was easily administered to each rabbit, and none of the animals seemed to develop an aversion to the treatment during the study. All of the rabbits seemed to remain healthy during the study, and none had changes in behavior, attitude, mentation, amount of activity, amount of food or water consumed, or fecal production that could be attributed to an adverse drug reaction. Significant differences were detected between baseline and posttreatment plasma BUN concentrations (mean ± SD, 11.0 ± 1.9 mg/dL and 13.7 ± 3.1 mg/dL, respectively) and alkaline phosphatase activities (mean ± SD, 109.3 ± 29.6 U/L and 143.5 ± 32.5 U/L, respectively). However, the mean baseline and posttreatment BUN concentrations were considered normal when compared with published reference ranges (13 to 29 mg/dL16; 15 to 50 mg/dL17). No significant differences were detected between baseline and posttreatment values of any other plasma biochemical analysis variables (Table 1).
Comparison of results of plasma biochemical analyses of samples collected from 6 rabbits before (baseline) and after (posttreatment) administration of meloxicam (1 mg/kg, PO) once per day for 5 days.
| Analyte | Baseline | Posttreatment | P value |
|---|---|---|---|
| Glucose (mg/dL) | 117 ± 21 | 117 ± 3.5 | 0.985 |
| BUN (mg/dL) | 11.0 ± 1.9 | 13.7 ± 3.1 | 0.010 |
| Creatinine (mg/dL) | 0.9 ± 0.23 | 0.9 ± 0.12 | 0.793 |
| Total protein (g/dL) | 5.2 ± 0.67 | 5.3 ± 0.28 | 0.671 |
| Albumin (g/dL) | 4.9 ± 0.86 | 5.1 ± 0.39 | 0.524 |
| Globulin (g/dL) | 0.35 ± 0.27 | 0.27 ± 0.24 | 0.363 |
| Calcium (mg/dL) | 12.6 ± 1.7 | 13.7 ± 0.77 | 0.063 |
| Phosphorus (mg/dL) | 4.9 ± 0.27 | 4.9 ± 0.45 | 0.752 |
| Sodium (mmol/L) | 151 ± 3.5 | 149 ± 1.9 | 0.282 |
| Potassium (mmol/L) | 4.2 ± 0.6 | 4.7 ± 0.23 | 0.057 |
| Chloride (mmol/L) | 108 ± 3.9 | 108 ± 3.1 | 0.830 |
| Bicarbonate (mmol/L) | 19.8 ± 2.8 | 19.7 ± 2.4 | 0.925 |
| Alanine aminotransferase (U/L) | 40 ± 15 | 41 ± 15 | 0.838 |
| Alkaline phosphatase (U/L) | 109.3 ± 29.6 | 143.5 ± 32.5 | 0.018 |
| Creatine kinase (U/L) | 526 ± 204 | 908 ± 498 | 0.056 |
| Total bilirubin (mg/dL) | 0.15 ± 0.37 | 0.03 ± 0.05 | 0.435 |
| Cholesterol (mg/dL) | 63 ± 25 | 48 ± 12 | 0.077 |
Data are mean ± SD.
The mean Cmax of meloxicam (0.83 μg/mL) was achieved 6.5 hours after oral administration of a single dose (1 mg/kg) of meloxicam (Figure 1). The harmonic mean of the terminal half-life was 6.1 hours, and the AUCinf was 10.37 h•μg/mL after administration of a single dose of meloxicam (Table 2).
Mean ± SD plasma concentrations of meloxicam in 6 rabbits following oral administration of 1 dose (1 mg/kg). Notice that the y-axis is not linear.
Citation: American Journal of Veterinary Research 74, 4; 10.2460/ajvr.74.4.636
Pharmacokinetic parameters of meloxicam in 6 rabbits that received 1 dose (1 mg/kg, PO) of the drug.
| Variable | Minimum | Median | Maximum | Mean* |
|---|---|---|---|---|
| AUCextrap (%) | 1.3 | 2.6 | 4.9 | 2.6 |
| AUCinf (h•μg/mL) | 8.44 | 10.72 | 12.45 | 10.37 |
| AUMC (h•h•μg/mL) | 96.37 | 121.93 | 169.16 | 126.75 |
| Cmax (μg/mL) | 0.65 | 0.85 | 1.02 | 0.83 |
| Terminal half-life (h) | 4.9 | 6.1 | 7.1 | 6.1 |
| λz (1/h) | 0.097 | 0.113 | 0.141 | 0.113 |
| MRT (h) | 10.6 | 11.8 | 14.7 | 12.2 |
| Tmax (h) | 4.0 | 7.0 | 8.0 | 6.5 |
All mean values are geometric mean except terminal half-life, which is harmonic mean.
AUCextrap = Percentage of the AUC extrapolated to infinity. AUMC = Area under the first moment curve extrapolated to infinity. MRT = Mean residence time extrapolated to infinity.
The mean ± SD plasma concentrations of meloxicam in plasma samples collected 4 hours after administration on days 1 through 5 of the multiple-dose experiment were 0.55 ± 0.16 μg/mL, 0.59 ± 0.20 μg/mL, 0.64 ± 0.21 μg/mL, 0.51 ± 0.11 μg/mL, and 1.05 ± 0.67 μg/mL, respectively. The mean ± SD plasma concentrations of meloxicam in plasma samples collected 24 hours after administration on days 1 through 5 of the multiple-dose experiment were 0.13 ± 0.03 μg/mL, 0.17 ± 0.06 μg/mL, 0.17 ± 0.04 μg/mL, 0.22 ± 0.1 μg/mL, and 0.32 ± 0.03 μg/mL, respectively (Figure 2).
Mean ± SD plasma concentrations of meloxicam in 6 rabbits following oral administration (1 mg/kg) once per day for 5 days. During the first 96 hours of the experiment, plasma samples were collected 4 and 24 hours after administration of meloxicam. During the last 24 hours of the experiment, plasma samples were collected 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, and 36 hours after administration of meloxicam. Notice that the y-axis is not linear.
Citation: American Journal of Veterinary Research 74, 4; 10.2460/ajvr.74.4.636
After administration of the last dose during the multiple-dose experiment, the mean Cmax of meloxicam was 1.33 μg/mL, the mean AUC was 16.08 h•μg/mL, the mean Tmax was 5.8 hours, and the harmonic mean of the terminal half-life was 6.7 hours. The mean ratio of the AUC0–24 (for the multiple dose experiment) to the AUCinf (for the single dose experiment) was 1.55; this value indicated meloxicam accumulated in plasma of the rabbits (Table 3).
Pharmacokinetic parameters of meloxicam in 6 rabbits that received 1 mg of meloxicam/kg once daily for 5 days.
| Variable | Minimum | Median | Maximum | Mean* |
|---|---|---|---|---|
| AUCextrap (%) | 1.5 | 3.9 | 4.8 | 3.1 |
| AUCinf (h•μg/mL) | 12.83 | 18.26 | 29.05 | 18.79 |
| AUC0–24 (h•μg/mL) | 11.32 | 15.79 | 25.88 | 16.08 |
| AUMC (h•h•μg/mL) | 154.49 | 229.98 | 451.24 | 244.41 |
| Cmax (μg/mL) | 0.77 | 1.27 | 2.57 | 1.33 |
| Terminal half-life (h) | 5.6 | 6.6 | 7.8 | 6.7 |
| λz (1/h) | 0.089 | 0.105 | 0.124 | 0.103 |
| MRT (h) | 11.7 | 12.6 | 16.4 | 13.0 |
| MRT0–24 (h) | 11.2 | 13.8 | 31.4 | 15.1 |
| Tmax (h) | 4.0 | 6.0 | 8.0 | 5.8 |
| AUC0–24/AUCinf | 1.27 | 1.47 | 2.08 | 1.55 |
| Cmax (multiple dose experiment)/Cmax (single dose experiment) | 0.99 | 1.72 | 2.89 | 1.61 |
Values indicate parameters after the last dose of meloxicam was administered.
MRT0–24 = Mean residence time from 0 to 24 hours.
See Table 2 for remainder of key.
Discussion
Results of this study indicated that oral administration of meloxicam at a dose of 1 mg/kg to rabbits caused plasma meloxicam concentrations that were proportionally higher than those attained after administration of the currently recommended12,13 dose (0.2 to 0.3 mg/kg). Moreover, the plasma concentrations of meloxicam measured in the study reported here were similar to those measured for animals of species that receive clinically effective doses.18–20 The clinical efficacy of meloxicam in rabbits was not determined in the present study. Further studies may be warranted in which the efficacy of orally administered meloxicam at a dose of 1 mg/kg in rabbits is assessed. Results of this study indicated that meloxicam accumulated in plasma of rabbits after 5 days of oral administration at a dose of 1 mg/kg. Further studies may be warranted to confirm results of the present study and to determine the pharmacokinetics of meloxicam for administration periods longer than 5 days.
Results of another study13 in which the pharmacokinetics of 1 dose of meloxicam (0.2 mg/kg, PO) in rabbits was determined indicated a mean ± SD Cmax of 0.17 ± 0.06 μg/mL and a mean ± SD AUC of 1.8 ± 0.5 h•μg/mL. Results of the present study indicated that administration of 1 dose of meloxicam that was 5-fold as high as the dose administered to rabbits in that other study caused a proportionally (ie, approx 5-fold) higher mean Cmax (0.83 μg/mL) and AUCinf (10.37 h•μg/mL). These findings indicated that an increase in an orally administered dose of meloxicam from 0.2 to 1 mg/kg caused a proportional increase in circulating concentrations of the drug.
The high mean Cmax value of meloxicam determined for rabbits in this study (0.83 μg/mL) was especially notable because of the similarity of that value to the Cmax values for clinically effective doses of meloxicam in other species. For example, the Cmax of meloxicam is 0.82 μg/mL for dogs that receive a clinically effective dose of 0.2 mg/kg.18 Additionally, investigators of a pharmacokinetic and pharmacodynamic study19 of meloxicam in cats estimated that plasma concentrations of 0.87 ± 0.3 μg/mL may inhibit ≥ 50% of the COX enzymes that are upregulated because of pain. Results of a study20 in which blood samples collected from adult humans that received clinically effective doses of meloxicam were analyzed indicated a Cmax of 0.88 to 1.92 μg/mL. Although plasma concentrations of meloxicam seemed to be similar in rabbits of the present study and animals of other species after administration of clinically effective doses in other studies, the effective meloxicam doses for animals of other species are lower than the dose administered to rabbits in this study. For example, clinically effective doses of meloxicam for 50- to 70-kg humans range from 0.1 to 0.3 mg/kg,21 and dogs are commonly treated with 0.1 to 0.2 mg of meloxicam/kg.2 Extrapolation of data for animals of other species should be performed cautiously, and assumptions regarding the clinical efficacy of meloxicam in rabbits should not be made on the basis of results of studies including animals of other species. Therefore, results of the present study should be used to design further studies to determine the efficacy of meloxicam (1 mg/kg, PO) in rabbits.
Results of the present study indicated that the AUC and Cmax were higher after administration of multiple doses of meloxicam than they were after administration of 1 dose of that drug. These findings suggested that meloxicam accumulated in plasma of rabbits after administration of multiple doses, which was consistent with results of one study13 but was not consistent with results of another study.12 These differences in results among studies may be attributable to ages of rabbits used in the studies. The rabbits used in the present study and the other study13 in which meloxicam accumulation in plasma was found were 8 months old, whereas rabbits used in the study12 with conflicting results were 3 months old. Further studies may be warranted in which the effects of age on the pharmacokinetics of meloxicam in rabbits are determined because female rabbits attain sexual maturity when they are 5 months old.22 Additionally, the mean and SD of the plasma concentration of meloxicam in plasma samples collected 4 hours after administration of the fifth dose of meloxicam in the multiple-dose experiment of the present study seemed to be higher than they were for plasma samples obtained at earlier times during that experiment. The reasons for this finding could not be determined. That finding may have been attributable to accumulation of meloxicam in rabbits, but the magnitude of the differences in values suggested that experimental factors may have also contributed. Factors such as alterations in feeding time, amount of stress, hydration status, or quantity of food ingested within a short period before or after drug administration may have contributed to that finding, although rabbits had no variations in husbandry or experimental procedures during the study to which that finding could be attributed, to the authors' knowledge.
The range of values of the meloxicam terminal half-life determined for rabbits during single- (4.9 to 7.1 hours) and multiple-dose (5.6 to 7.8 hours) experiments in the present study was within the range of values determined for rabbits in another study,13 although the range of values in that other study was large (4.5 to 42 hours). The time to peak plasma meloxicam concentration was slightly longer for rabbits of the present study (approx 6 hours) than it was for rabbits in that other study13 (4 hours). Because the meloxicam Tmax for rabbits was approximately 6 hours in the study reported here, the meloxicam Cmax was not determined for days 1 to 4 of the multiple-dose experiment because blood samples were obtained 4 hours after drug administration during those days.
Results of plasma biochemical analyses in the present study indicated BUN concentrations and alkaline phosphatase activities for rabbits were significantly higher in posttreatment plasma samples than they were in baseline plasma samples. These findings may have been attributable to physiologically normal variations in values or to experimental factors (housing, collection of multiple blood samples, handling, or stress of rabbits associated with experimental procedures) rather than the effects of meloxicam. A control (untreated) group of rabbits was not included in this study; therefore, the effects of those experimental factors could not be determined. However, plasma BUN concentrations were lower than the upper limit of the reference range for rabbits,16,17 and both baseline and posttreatment plasma alkaline phosphatase activities were higher than the reference range for rabbits,16,17 suggesting that increases in values of these analytes were not attributable to experimental procedures. Potential causes for high circulating alkaline phosphatase activities include hepatic induction, hepatobiliary disease, bone formation, or physiologically normal variation among animals. Because plasma values of other biochemical analysis hepatic analytes (eg, alanine aminotransferase activity and total bilirubin and albumin concentrations) were within the reference ranges for rabbits of the present study, it was unlikely that increases in plasma alkaline phosphatase activities were attributable to meloxicam-induced liver damage.23,24 In addition, the range of values included in the SDs of the posttreatment plasma sample BUN concentrations and alkaline phosphatase activities included the baseline plasma sample values, and the statistically significant increases in the values of these variables may not have indicated clinically relevant changes. In addition, the rabbits of this study did not develop clinical signs attributable to adverse effects of meloxicam. Rabbits undergoing surgery, geriatric rabbits, or rabbits with preexisting diseases may be at a greater risk for adverse effects of meloxicam versus rabbits without those factors; therefore, further studies may be warranted to determine the clinical safety of meloxicam for rabbits.
In the multiple-dose experiment of the present study, the value for meloxicam accumulation was expected to be approximately 1.33 as determined on the basis of the expected ratio of the terminal half-life and the dosing interval. Accumulation of meloxicam was determined via calculation of the ratio of AUC0–24 to AUCinf. The reason the AUC0–24 (for the multiple-dose experiment) was used for determination of meloxicam accumulation was to account for residual amounts of meloxicam in plasma from previously administered doses. If steady-state concentration had been achieved, the AUC0–24 would have been equivalent to the AUCinf at 24 hours after administration of 1 dose. The observed accumulation value was larger than expected (mean, 1.55; range, 1.27 to 2.08) on the basis of the AUCs. This finding suggested that accumulation of meloxicam varied among rabbits of this study. Long-term administration of meloxicam to rabbits was not evaluated in this study, but the potential for drug accumulation in rabbits may warrant reduction of the dose if meloxicam is administered for > 5 days. Further studies are warranted to determine the safety of meloxicam (1 mg/kg, PO) for various treatment durations.
Nonsteroidal anti-inflammatory drugs (eg, meloxicam, carprofen, and ketoprofen) are commonly prescribed for short- and long-term pain control in animals. Meloxicam is commonly administered to rabbits because it is readily available in a palatable liquid preparation that is easy to administer. The peak plasma concentration of meloxicam after oral administration to rabbits of this study was similar to the peak plasma concentration in animals of other species after administration of a clinically effective dose. Oral administration of 1 mg of meloxicam/kg was well tolerated by rabbits of this study. Findings of the study suggested that oral administration of 1 mg of meloxicam/kg may be necessary to attain clinically effective circulating concentrations in rabbits. However, that meloxicam dose should be evaluated in further studies to determine safety and clinical efficacy for rabbits.
ABBREVIATIONS
| AUC | Area under the plasma concentration-versus time curve |
| AUC0–24 | Area under the plasma concentration-versus time curve from administration of the last of 5 doses to 24 hours after administration of the last dose |
| AUCinf | Area under the plasma concentration-versus-time curve extrapolated to infinity after administration of a single dose |
| Cmax | Observed maximum plasma concentration |
| COX | Cyclooxygenase |
| λz | Plasma terminal rate constant |
| Tmax | Time to reach maximum plasma concentration |
Bunny Basics 15/23, Oxbow Pet Products, Murdock, Neb.
Western Timothy Hay, Oxbow Pet Products, Murdock, Neb.
Metacam 1.5 mg/mL oral suspension, Boehringer Ingelheim Vetmedica, St Joseph, Mo.
Shimadzu Prominence, Shimadzu Scientific Instruments Inc, Columbia, Md.
API 2000, Applied Biosystems Inc, Foster City, Calif.
Supelco Discovery C8, 50 × 2.1 mm, 5 μm, Sigma-Aldrich Corp, St Louis, Mo.
WinNonlin, version 5.2, Pharsight Corp, Mountain View, Calif.
References
1. Doig PA, Purbrick KA & Hare JE, et al. Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis. Can Vet J 2000; 41:296–300.
2. Gruet P, Seewald W, King JN. Evaluation of subcutaneous and oral administration of robenacoxib and meloxicam for the treatment of acute pain and inflammation associated with orthopedic surgery in dogs. Am J Vet Res 2011; 72:184–193.
3. Mathews KA, Pettifer G & Foster R, et al. Safety and efficacy of preoperative administration of meloxicam, compared with that of ketoprofen and butorphanol in dogs undergoing abdominal surgery. Am J Vet Res 2001; 62:882–888.
4. Reid J, Nolan AM. A comparison of the postoperative analgesic and sedative effects of flunixin and papaveretum in the dog. J Small Anim Pract 1991; 32:603–608.
5. Gates BJ, Nguyen TT & Stetter SM, et al. Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. Expert Opin Pharmacother 2005; 6:2117–2140.
6. Jones CJ, Budsberg SC. Physiologic characteristics and clinical importance of the cyclooxygenase isoforms in dogs and cats. J Am Vet Med Assoc 2000; 217:721–729.
7. Curry SL, Cogar SM, Cook JL. Nonsteroidal antiinflammatory drugs: a review. J Am Anim Hosp Assoc 2005; 41:298–309.
8. Jones CJ, Streppa HK & Harmon BG, et al. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs. Am J Vet Res 2002; 63:1527–1531.
9. Solomon DH, Gurwitz JH. Toxicity of nonsteroidal antiinflammatory drugs in the elderly: is advanced age a risk factor? Am J Med 1997; 102:208–215.
10. Johnston MS. Clinical approaches to analgesia in ferrets and rabbits. J Exot Pet Med 2005; 14:229–235.
11. Frost EA. Preventing paralytic ileus: can the anesthesiologist help. Middle East J Anesthesiol 2009; 20:159–165.
12. Turner PV, Chen HC, Taylor MW. Pharmacokinetics of meloxicam in rabbits after single and repeat oral dosing. Comp Med 2006; 56:63–67.
13. Carpenter JW, Pollock CG & Koch DE, et al. Single and multiple-dose pharmacokinetics of meloxicam after oral administration to the rabbit (Oryctolagus cuniculus). J Zoo Wildl Med 2009; 40:601–606.
14. Gibaldi M, Perrier P. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc, 1982; 409–417.
15. Riviere JE. Comparative pharmacokinetics: principles, techniques, and applications. Ames, Iowa: Iowa State University Press, 1999; 148–167.
16. Graham J, Mader DR. Basic approach to veterinary care. In: Quesenberry KE, Carpenter JW, eds. Ferrets, rabbits, and rodents: clinical medicine and surgery. 3rd ed. St Louis: Elsevier, 2012; 174–182.
17. Fiorello CV, Divers SJ. Rabbits. In: Carpenter JW, ed. Exotic animal formulary. 4th ed. St Louis: Elsevier, 2012; 517–559.
18. Montoya L, Ambrose L & Kreil V, et al. A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. Vet Res Commun 2004; 28:415–428.
19. Giraudel JM, Diquelou A & Laroute V, et al. Pharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat. Br J Pharmacol 2005; 146:642–653.
20. Burgos-Vargas R, Foeldvari I & Thon A, et al. Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis. J Clin Pharmacol 2004; 44:866–872.
21. Chen YF, Jobanputra P & Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008; 12:1–278.
22. Vella D, Donnelly T. Basic anatomy, physiology, and husbandry. In: Quesenberry KE, Carpenter JW, eds. Ferrets, rabbits, and rodents: clinical medicine and surgery. 3rd ed. St Louis: Elsevier, 2012; 157–173.
23. MacPhail CM, Lappin MR & Meyer DJ, et al. Hepatocellular toxicosis associated with administration of carprofen in 21 dogs. J Am Vet Med Assoc 1998; 212:1895–1901.
24. Luna SPL, Basilio AC & Steagall PVM, et al. Evaluation of adverse effects of long-term oral administration of carprofen, edodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. Am J Vet Res 2007; 68:258–264.
